Skip to content

13F-HR filed by Stonepine Capital Management, LLC

Stonepine Capital Management, LLC filed this 13F-HR for the quarter ended 2019-06-30, filed 2019-08-13, with 25 holding rows worth $145,241,000.

Accession
0001567619-19-016550
Filed
2019-08-13
Accepted by EDGAR
acceptance time not in the bulk data set
Ingested
Source
SEC quarterly data set

Original filing

13F report for Q2 2019

A holdings report, 25 entries on the cover page, a total value of $145,241,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $145,241,000 with VALUE read as thousands by filing date, 13F file number 028-17175. The quarter's positions are built on this report. The resolved quarter.

The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).

Issuer as filedCUSIPClassAmountValueValue read asType
LIGAND PHARMACEUTICALS INC53220K504COM NEW167,487$19,119,000thousands by filing date
VANDA PHARMACEUTICALS INC921659108COM1,341,943$18,908,000thousands by filing date
AMARIN CORP PLC023111206SPONS ADR NEW930,604$18,044,000thousands by filing date
BIODELIVERY SCIENCES INTL IN09060J106COM2,764,475$12,855,000thousands by filing date
ADAMAS PHARMACEUTICALS INC00548A106COM1,423,578$8,826,000thousands by filing date
APOLLO ENDOSURGERY INC03767D108COM2,580,518$8,387,000thousands by filing date
NEOS THERAPEUTICS INC64052L106COM4,971,014$6,413,000thousands by filing date
ALIMERA SCIENCES INC016259103COM6,439,498$5,731,000thousands by filing date
CUMBERLAND PHARMACEUTICALS I230770109COM871,762$5,553,000thousands by filing date
ENANTA PHARMACEUTICALS INC29251M106COM65,484$5,526,000thousands by filing date
IVERIC BIO INC46583P102COM4,113,522$5,348,000thousands by filing date
HTG MOLECULAR DIAGNOSTICS IN40434H104COM2,785,585$4,624,000thousands by filing date
OPIANT PHARMACEUTICALS INC683750103COM315,468$4,180,000thousands by filing date
XOMA ROYALTY CORPORATION98419J206COMMON STOCK270,449$4,019,000thousands by filing date
APTEVO THERAPEUTICS INC03835L108COM3,922,891$3,478,000thousands by filing date
CTI BIOPHARMA CORP12648L601COM3,904,400$3,355,000thousands by filing date
OXFORD IMMUNOTEC GLOBAL PLCG6855A103ORD SHS227,900$3,136,000thousands by filing date
AFFIMED N VN01045108COM715,754$2,054,000thousands by filing date
FOAMIX PHARMACEUTICALS LTDM46135105SHS651,211$1,550,000thousands by filing date
VIVEVE MED INC92852W204COM NEW3,403,402$1,293,000thousands by filing date
INTERPACE DIAGNOSTICS GROUP46062X204COM NEW1,753,184$1,271,000thousands by filing date
MATINAS BIOPHARMA HLDGS INC576810105COM668,615$573,000thousands by filing date
STRONGBRIDGE BIOPHARMA PLCG85347105SHS USD162,244$508,000thousands by filing date
NOVELION THERAPEUTICS INC67001K202COM NEW491,096$383,000thousands by filing date
MOTUS GI HLDGS INC62014P108COM35,205$107,000thousands by filing date

Amendment chain

FilingRoleFiledAcceptedIngested
13F-HR 0001567619-19-016550this filing2019-08-13acceptance time not in the bulk data set